Sarcoidosis is an inflammatory condition in which clusters of immune cells form small nodules, or granulomas, within the lungs and nearby lymph nodes. The exact cause remains unclear, but research suggests that both genetic factors and environmental exposures may play a role in triggering abnormal immune responses. Pulmonary manifestations vary widely: some individuals show no symptoms while others experience persistent cough, shortness of breath, chest discomfort, or fatigue. Diagnosis of sarcoidosis lung disease requires a careful combination of high-resolution imaging to assess lung structure, pulmonary function tests to measure airflow and gas exchange, and tissue biopsy to confirm the presence of granulomatous inflammation while excluding infections or malignancies. Early detection is essential to prevent irreversible lung changes and maintain long-term respiratory function, particularly when other organs may also be affected.
Management strategies aim to reduce inflammation, preserve lung capacity, and improve daily functioning. Corticosteroids are commonly used to treat moderate to severe cases, and immunosuppressive medications can be considered for patients who do not respond to steroids or experience side effects. Supportive interventions, including supplemental oxygen, pulmonary rehabilitation, and targeted exercise programs, help patients maintain strength and respiratory efficiency. Regular follow-up with imaging and lung function assessment ensures that disease progression or relapse is promptly addressed. Coordinated care involving pulmonologists, rheumatologists, and other specialists allows treatment to be individualized, balancing effectiveness with safety. These comprehensive approaches help patients achieve disease stability, prevent long-term complications, and maintain overall lung health.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation